Affimed (AFMD) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Affimed has reported encouraging results from their study, showing that their combination therapy of AFM24 and atezolizumab produced durable responses in heavily pretreated non-small cell lung cancer (NSCLC) patients. The therapy showed a manageable safety profile and suggests potential as an alternative treatment strategy for NSCLC patients resistant to existing therapies. The company continues to enroll patients in the study, with further updates expected later in the year.
For further insights into AFMD stock, check out TipRanks’ Stock Analysis page.